Investigational Drug Information for Aumolertinib
✉ Email this page to a colleague
What is the development status for investigational drug Aumolertinib?
Aumolertinib is an investigational drug.
There have been 16 clinical trials for Aumolertinib.
The most recent clinical trial was a Phase 1 trial, which was initiated on October 1st 2025.
The most common disease conditions in clinical trials are Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, and Liver Diseases. The leading clinical trial sponsors are Jiangsu Hansoh Pharmaceutical Co., Ltd., EQRx, Inc., and The First Affiliated Hospital of Guangzhou Medical University.
There are thirty-six US patents protecting this investigational drug and seventy-three international patents.
Summary for Aumolertinib
| US Patents | 36 |
| International Patents | 73 |
| US Patent Applications | 158 |
| WIPO Patent Applications | 180 |
| Japanese Patent Applications | 1 |
| Clinical Trial Progress | Phase 1 (2025-10-01) |
| Vendors | 46 |
Recent Clinical Trials for Aumolertinib
| Title | Sponsor | Phase |
|---|---|---|
| A Study of SHR-A2009 Combined With Aumolertinib Versus Aumolertinib for First-line Treatment in EGFR-mutated, Advanced or Metastatic NSCLC | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | PHASE3 |
| A Study Evaluating the Effect of Aumolertinib on the Pharmacokinetics of Midazolam in Patients With NSCLC | Jiangsu Hansoh Pharmaceutical Co., Ltd. | PHASE1 |
| A Study of Aumolertinib in European Participants With Non-Small Cell Lung Cancer | Jiangsu Hansoh Pharmaceutical Co., Ltd. | PHASE1 |
Clinical Trial Summary for Aumolertinib
Top disease conditions for Aumolertinib
Top clinical trial sponsors for Aumolertinib
US Patents for Aumolertinib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Aumolertinib | ⤷ Start Trial | EGFR inhibitor, preparation method and use thereof | Jiangsu Hansoh Pharmaceutical Group Co Ltd , Shanghai Hansoh Biomedical Co Ltd | ⤷ Start Trial |
| Aumolertinib | ⤷ Start Trial | EGFR inhibitor, preparation method and use thereof | Jiangsu Hansoh Pharmaceutical Group Co Ltd , Shanghai Hansoh Biomedical Co Ltd | ⤷ Start Trial |
| Aumolertinib | ⤷ Start Trial | EGFR inhibitor free base or acid salt polycrystalline form, preparation method therefor, and application | Jiangsu Hansoh Pharmaceutical Group Co Ltd , Shanghai Hansoh Biomedical Co Ltd | ⤷ Start Trial |
| Aumolertinib | ⤷ Start Trial | EGFR inhibitor free base or acid salt polycrystalline form, preparation method therefor, and application | Jiangsu Hansoh Pharmaceutical Group Co Ltd , Shanghai Hansoh Biomedical Co Ltd | ⤷ Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Aumolertinib
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Aumolertinib | Australia | AU2015330506 | 2034-10-11 | ⤷ Start Trial |
| Aumolertinib | Brazil | BR112017006713 | 2034-10-11 | ⤷ Start Trial |
| Aumolertinib | Canada | CA2959194 | 2034-10-11 | ⤷ Start Trial |
| Aumolertinib | China | CN106661000 | 2034-10-11 | ⤷ Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
